|Cells||Cor.4U@ human iPS-derived cardiomyocytes|
|Species||Human (mouse possible, please inquire)|
|Service Content||Investigation of a compound's effect on spontaneous beating (frequency, amplitude, rhythmicity) of Cor.4U cardiomyocytes using ACEA's xCELLigence RTCA Cardio instrument|
|Delivery||A study protocol will be sent to initiate the study. Results are sent as draft and final study report.|
|Timelines||Experiment time: 2 weeks per compound.
Draft report: within 4 weeks
Cor.4U® human iPS cell-derived cardiomyocytes in combination with the xCELLigence RTCA Cardio instrument provide a standardized, homogenous and reproducible assay system for the in vitro detection of a compound‘s potential to influence cardiomyocyte function. Results obtained in the study will indicate a potential effect on cardiac beating, e.g. changes of beating frequency, spike amplitude, induction of arrhythmia, or beating arrest.
Axiogenesis' stem cell-derived cardiomyocytes provide a physiologically relevant and predictive in vitro model for cardiac safety screening in early lead optimization. Results obtained in our electrophysiology assays can be compared directly with results obtained in our cellular toxicity assays. This improves the ability to determine potential cardiotoxic effects of compounds in early stages of drug development, providing better measures to move lead compounds towards pre-clinical and clinical development.
The CardioEffect Screening has been validated in house using 24 drugs with known cardiac safety profile. Reference compounds are included on each assay plate to ensure reproducible results.
Fig. 1: Application of different concentrations of E-4031 (Cor.4U@ xCELLigence assay)